Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Heron Therapeutics (HRTX) Receivables - Net (2016 - 2025)

Heron Therapeutics' Receivables - Net history spans 11 years, with the latest figure at $89.6 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 13.57% year-over-year to $89.6 million; the TTM value through Dec 2025 reached $89.6 million, up 13.57%, while the annual FY2025 figure was $89.6 million, 13.57% up from the prior year.
  • Receivables - Net reached $89.6 million in Q4 2025 per HRTX's latest filing, up from $81.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $89.6 million in Q4 2025 to a low of $35.5 million in Q4 2021.
  • Average Receivables - Net over 5 years is $60.1 million, with a median of $62.0 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: dropped 15.18% in 2021, then surged 90.29% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $35.5 million in 2021, then surged by 46.62% to $52.0 million in 2022, then increased by 15.54% to $60.1 million in 2023, then surged by 31.17% to $78.9 million in 2024, then rose by 13.57% to $89.6 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Receivables - Net are $89.6 million (Q4 2025), $81.0 million (Q3 2025), and $79.9 million (Q2 2025).